Voor meer informatie of vragen kan je contact opnemen met CTO via cto(at)gza.be of op het nummer 03 443 37 59.
OPEN VOOR INCLUSIE
7/3/2024 - Shapers- Efficacy and safety of short-course radiotherapy (SCRT) versus total neoadjuvant therapy in older patients with locally advanced rectal cancer: a multicentre open-label, randomised pragmatic clinical trial.
13/12/2023 - Thunder - Treatment of Hig-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial
24/11/2023 - ReCare - ReCare is a cohort within E²-RADIatE and focuses on cancer patients who are treated with high-dose re-irradiation.
27/7/2023 - CASTAR - CArdiac STereotactic radiation treatment for Ablation of ventRicular tachycardia
8/2/2023 - NARCiS - Neurocognition after radiotherapy in adult brain and base of skull tumours
6/2/2023 - EFFORT-MICB - Phase II prospective trial to evaluate the impact of 18F-FDG-PET-CT in stratifying patients with primary muscle invasive bladder cancer and tailoring the treatment accordingly.
15/3/2022 - SABR-MESCC - Separation surgery followed by Stereotactic Ablative Body Radiotherapy versus Stereotactic Ablative Body Radiotherapy alone for spinal metastases invading the spinal canal: a randomised, non-inferiority trial (SABR-MESCC).
6/10/2021 - PRIMALung-studie - Profylactische cerebrale bestraling of actieve opvolging met magnetische resonantiebeeldvorming bij patiënten met kleincellige longkanker (PRIMALung-studie).
29/9/2021 - OligoRARE - Stereotactic bodyradiotherapy in addition to standard of care tretment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial
1/6/2021 - OligoCare E²-RADIatE - OligoCare: A pragmatic observational cohort study to evaluate radical radiotherapy for oligo-metastatic cancer patients
9/2/2021 - DART - Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial
25/3/2019 - SAVE - A Phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of andorgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomy.
1/3/2019 - SBRT LEVERMETASTASEN - National registration of patients with liver metastases treated with stereotactic body radiation therapy.
GESLOTEN VOOR INCLUSIE
1/6/2020 - IMMUNO SABR - Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non small cell lung cancer.
2/2/2024 - STAR-TREC - Can we Save the rectum by watchful waiting or TransAnal microsurgery following (chemo)Radiotherapy versus Total mesorectal excision for early Rectal Cancer?
15/2/2022 - PRIMORDIUM - A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients Protocol
22/4/2022 - Neo-Checkray - Neo-adjuvant chemotherapy combined with SBRT to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab (MEDI9447) in luminal B breast cancer: a phase II randomized trial.
13/5/2024 IORT PARTIAL BREAST RT - Oncological outcome and cosmesis after intraoperative partial breast irradiation in early stage breast cancer patients: a prospective observational study.
25/3/2019 - ROBOMET - Improving quality of life with stereotactic Radiation oncology for Bone metastates.
4/3/2019 - DOSIS RCT-SPINE SBRT - Dose intensified Image-guided fractionated Stereotactic body radiation therapy for painful spinal metastases versus conventional radiation therapy: a phase II randomised controlled trial
8/5/2019 - PEGASUS - A Phase 2, Randomized, Open-label, 3-arm Study to Assess the Efficacy and Safety of relacorilant in Combination with Nab-paclitaxel for Patients with Platinum-resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
26/1/2021 - DEBIO 1143-301 - A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX).
1/9/2020 - ENGOT-cx11/MK3475-A18 - A randomized, phase 3, double-blind study of chemoradiotherapy with or without Pembrolizumab for the treatment of high-risk, locally advanced cervical cancer
9/12/2020 - EORTC1740 - Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Maintenance Durvalumab versus Durvalumab plus Radiotherapy followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer
14/12/2020 - EORTC-1635-BTG - "IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? The I-WOT study"
23/10/2018 - EORTC1709 - A phase III trial of marizomib in combinaton with standard temozolomide-base radiochemotherapy vs standard temozolomide-base radiochemotherapy alone in patients with newly diagnosed glioblastoma.
10/8/2018 - TORM- PEACE V: A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM)
11/7/2018 - ROAM-EORTC1308-ROG - Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial.
30/3/2016 - ATLAS - 56021927PCR3003 - A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy.
1/1/2016 - ADJ RT BLAASCA UZ GENT - Adjuvant radiotherapy after cystectomy for patients with muscle invasive bladder cancer: a phase II trial.
Voor meer informatie of vragen kan je contact opnemen met CTO via cto(at)gza.be of op het nummer 03 443 37 59.
OPEN VOOR INCLUSIE
07/03/2024 - SHAPERS- Efficacy and safety of short-course radiotherapy (SCRT) versus total neoadjuvant therapy in older patients with locally advanced rectal cancer: a multicentre open-label, randomised pragmatic clinical trial.
13/12/2023 - Thunder - Treatment of Hig-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial
24/11/2023 - ReCare - ReCare is a cohort within E²-RADIatE and focuses on cancer patients who are treated with high-dose re-irradiation.
27/07/2023 - CASTAR - CArdiac STereotactic radiation treatment for Ablation of ventRicular tachycardia
08/02/2023 - NARCiS - Neurocognition after radiotherapy in adult brain and base of skull tumours
06/02/2023 - EFFORT-MICB - Phase II prospective trial to evaluate the impact of 18F-FDG-PET-CT in stratifying patients with primary muscle invasive bladder cancer and tailoring the treatment accordingly.
15/03/2022 - SABR-MESCC -Separation surgery followed by Stereotactic Ablative Body Radiotherapy versus Stereotactic Ablative Body Radiotherapy alone for spinal metastases invading the spinal canal: a randomised, non-inferiority trial (SABR-MESCC).
06/10/2021 -PRIMALung-studie - Profylactische cerebrale bestraling of actieve opvolging met magnetische resonantiebeeldvorming bij patiënten met kleincellige longkanker
(PRIMALung-studie).
29/09/2021 - OligoRARE -Stereotactic bodyradiotherapy in addition to standard of care tretment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial
06/2021 - OligoCare E²-RADIatE -OligoCare: A pragmatic observational cohort study to evaluate radical radiotherapy for oligo-metastatic cancer patients
09/02/2021 - DART- Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial
25/03/2019 - SAVE- A Phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of andorgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomy.
SBRT LEVERMETASTASEN- National registration of patients with liver metastases treated with stereotactic body radiation therapy.
GESLOTEN VOOR INCLUSIE
06/2020 - IMMUNO SABR- Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non small cell lung cancer.
02/02/2024 - STAR-TREC - Can we Save the rectum by watchful waiting or TransAnal microsurgery following (chemo)Radiotherapy versus Total mesorectal excision for early Rectal Cancer?
15/02/2022 - PRIMORDIUM -A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients Protocol
22/04/2022 - Neo-Checkray -Neo-adjuvant chemotherapy combined with SBRT to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab (MEDI9447) in luminal B breast cancer: a phase II randomized trial.
IORT PARTIAL BREAST RT- Oncological outcome and cosmesis after intraoperative partial breast irradiation in early stage breast cancer patients: a prospective observational study.
25/03-2019 - ROBOMET- Improving quality of life with stereotactic Radiation oncology for Bone metastates.
04/03/2019 - DOSIS RCT-SPINE SBRT- Dose intensified Image-guided fractionated Stereotactic body radiation therapy for painful spinal metastases versus conventional radiation therapy: a phase II randomised controlled trial
08/05/2019 - PEGASUS- A Phase 2, Randomized, Open-label, 3-arm Study to Assess the Efficacy and Safety of relacorilant in Combination with Nab-paclitaxel for Patients with Platinum-resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
26/01/2021 - DEBIO 1143-301- A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX).
09/2020 - ENGOT-cx11/MK3475-A18- A randomized, phase 3, double-blind study of chemoradiotherapy with or without Pembrolizumab for the treatment of high-risk, locally advanced cervical cancer
09/12/2020 - EORTC1740- Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Maintenance Durvalumab versus Durvalumab plus Radiotherapy followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer
14/12/2020 - EORTC-1635-BTG- "IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? The I-WOT study"
13/12/2018 - CHEERS- CHEckpoint inhibition in combination with an immunoboost of External body Radiotherapy in Solid tumors: CHEERS-trial. Een bestralingsboost na 4 cycli immuuntherapie.
23/10/2018 - EORTC1709- A phase III trial of marizomib in combinaton with standard temozolomide-base radiochemotherapy vs standard temozolomide-base radiochemotherapy alone in patients with newly diagnosed glioblastoma.
10/08/2018 - STORM- PEACE V: A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM)
11/07/2018 - ROAM-EORTC1308-ROG- Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial.
30/03/2016 - ATLAS - 56021927PCR3003- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy
01/01/2016 - ADJ RT BLAASCA UZ GENT- Adjuvant radiotherapy after cystectomy for patients with muscle invasive bladder cancer: a phase II trial.
